Clinical trials
Non-small Cell Lung Cancer Stage III clinical trials
Below are recruiting non-small cell lung cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 236 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07167459Enrolling by invitationPhase 2
Personalized radiation for early stage lung cancer
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03851445RecruitingPhase 2/Phase 3
Lung cancer screening trial using tumor and blood test results
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
Birmingham, AlabamaAges 18 years+ - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT07039656RecruitingPhase 2
Toripalimab plus chemo after NSCLC surgery
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Guangzhou, GuangdongAges 18–75 - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT06734702RecruitingPhase 3
Immunotherapy before chemo-radiation for advanced lung cancer
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT06576635Recruiting
Chemotherapy study for advanced lung cancer
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Chicago, IllinoisAges 18 years+ - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT05987345Recruiting
Pulsed electric field therapy for advanced lung cancer after immunotherapy
This trial tests a new treatment called pulsed electric field therapy for people with advanced lung cancer (stage III or IV) that has not responded to first-line immunotherapy. It uses targeted electrical pulses to destroy tumor cells, and may be an option for those who still have other measurable tumors.
Guangzhou, GuangdongAges 22 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT06582771RecruitingPhase 2
Testing sotorasib for untreated lung cancer with KRAS G12C mutation
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
Basking Ridge, New JerseyAges 18 years+ - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06907160Recruiting
Chemotherapy plus immunotherapy before lung cancer surgery
This trial tests a combination of chemotherapy and immunotherapy given before surgery for stage II or III non-small cell lung cancer. Doctors will look at biomarkers in your blood and tissue to see how the cancer responds, which could help guide future treatments.
SeoulAges 19 years+ - NCT07122687RecruitingPhase 2
IBI363 or Pembrolizumab with Chemo before Lung Cancer Surgery
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
Shenyang, LiaoningAges 18–75 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07224152RecruitingPhase 1/Phase 2
NBTXR3 plus radiation for inoperable lung cancer
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
Houston, TexasAges 18 years+
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell lung cancer stage iii?
- Yes. Clin2 currently lists 236 recruiting non-small cell lung cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell lung cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell lung cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Unresectable Stage III Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.